The interest in the study of Rhesus disease arises from the aspiration to understand blood and its components at the cellular level. To recognize which factors lead to this disease and which components of the cell can be used as indicators/markers to diagnose it, it is necessary to have a general idea of ​​the concepts involved in cellular processes. This article will focus on the causes of hemolytic disease, including natural and/or surgical and medicinal events that cause isoimmunization; How antigens and antibodies are involved and the effectiveness of Rh immunoglobulin will also be taken into consideration. The nature of Rhesus disease or Rh isoimmunization comes from the Rh factor, which is a protein that can be found on the surface of red blood cells. Carrying this protein means that a person is Rh⁺ while a person who does not carry the protein is Rh⁻. Rh status is determined by the mother and father; if one parent is Rh⁺ and the other is Rh⁻, the child has at least a 50% chance of being Rh⁺. Since people are genetically predetermined to have or not have the Rh factor, sometimes there is an event where a woman who is Rh⁻ is pregnant with a child who is Rh⁺. Problems can then arise if the baby's blood enters the mother's bloodstream; the baby's Rh⁺ blood causes the mother's body to create antibodies against it. These antibodies will then attack any Rh⁺ blood cells. This does not cause any harm to the mother, but can create complications for the baby if the antibodies pass to the baby and destroy some of her blood cells. This is what is called isoimmunization; only occurs if the baby's Rh⁺ blood enters the bloodstream, unless a woman becomes sensitized to Rh blood when she has received an incompatible disease...... middle of paper ......y vincible. Works CitedArthur, G.R., Foote, G., Page, C., Scott, J.S., Thornton, J.G., Tovey, L.A. 1989. Efficacy and long-term effects of antenatal prophylaxis with anti-D immunoglobulin. British medical journal. V.298 (6689). Pages 1671-1673. Clinical and experimental immunology. 1983. IUSI/WHO Notice: Appropriate uses of human immunoglobulin in clinical practice. The Journal of Translational Immunology. V.52(2). Pages 417-422.Holder, W.T., McCord, D.L. and Turner, Ralph J. 1984. Isoimmunization with anti-U antibody. Journal of the National Medical Association. V.76 (3). Pages 277-283.Perinatol, J. 2011. Fetal intraperitoneal injection of immunoglobulin decreases alloimmune hemolysis. Journal of Perinatology. V. 31. Pages 289-292.Whitehouse, WL 1968. Rhesus isoimmunization and therapeutic abortion. British medical journal. V.2 (5659). Page. 759-760.